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ess: acapelas@hgda.osaSummary Study objetives: The goal of this study was to assess variability in the
management of patients admitted to hospitals with community-acquired pneumonia
(CAP), and changes in secular trends of this condition.
Methods: Observational study carried out, in 5 teaching hospitals, in northern
Spain of patients admitted with CAP between March 1,1998 and March 1,1999
(baseline period), and between March 1, 2000 and September 30, 2001 (follow-up
period). Clinical histories were analyzed retrospectively for relevant parameters for
process-of-care and outcome performance. Those parameters among hospitals
during the baseline period were compared. For each hospital, changes in these
parameters between baseline and follow-up were also measured. All parameters
were adjusted for disease severity.
Results: A total of 844 patients were included in the baseline period, and 654 in
the follow-up period. During the baseline period, adjusted analyses revealed
statistically significant differences in all process-of-care parameters except the
coverage of atypical pathogens. With regard to clinical outcomes, however, only the
30-day readmission rate was significantly different (P ¼ 0:03). Adjusted mean length
of stay ranged from 6.3 to 9.2 days (Po0:0001). In adjusted analyses of temporal
changes within hospitals for process-of-care and outcome performance, revealed
few statistically significant differences.
Conclusions: Variability discovered between hospitals in the management of
patients in the absence of relevant secular changes in each hospital points out theElsevier Ltd. All rights reserved.
4007002; fax: +34-944007132
kidetza.net (A. Capelastegui).
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CAP management variability 269necessity to implement measures designed to reduce such variability between
hospitals and to improve the quality of medical treatment.
& 2004 Elsevier Ltd. All rights reserved.Introduction
Community-acquired pneumonia (CAP) is a disease
with substantial morbidity, mortality, and economic
impact. Given that it is a common disease with a
well-known natural history, well-defined care pro-
visions, and an effective and internationally agreed
upon treatment, it is surprising to find considerable
variability in its management, both across countries
as well as between different hospitals in the same
country.1–9
The latest generations of guidelines for CAP have
been developed using a more rigorous and systema-
tic approach.10–12 Although judgment and consen-
sus remain important in making recommendations,
all coincide in identifying the most important
components of the process of care. Yet previous
studies have shown important differences among
hospitals in the admission decision,4–6 the length of
stay,1–4 and the management of antibiotics.7–9
These variations cannot be attributed exclusively
to patient-related factors. The available informa-
tion on variation in care comes mainly from studies
carried out in North America; little such informa-
tion is available from studies conducted in Europe.
A related and highly relevant factor when study-
ing variability in CAP is the management evolution
over time. Thus, some studies have documented
that in a competitive environment such as that
found in the USA, secular trends have led to
changes in the administration of care13 or reduction
in the average length of stay.14,15 Better under-
standing of the secular changes associated with the
clinical practice of CAP management in European
hospitals would reinforce the need for implement-
ing improvement strategies if needed.
In this regard, we analyzed retrospectively the
differences in both process of care and outcome
variables between several hospitals. We also
evaluated and compared the evolution of these
variables over time.Methods
Study and design
This study was carried out in 5 teaching general
hospitals with similar human and technical re-sources located in the Basque Country (northern
Spain): Hospital A, 450 beds, 250 000 reference
population, urban/rural type of population; Hospi-
tal B, 650 beds, 600 000 reference population,
urban type of population; Hospital C, 900 beds,
500 000 reference population, urban/rural type of
population; Hospital D, 1000 beds, 600 000 refer-
ence population, urban/rural type of population;
Hospital E, 400 beds, 300 000 reference population,
urban/rural type of population. The general and
diagnostic services are comparable in the five
hospitals. These medical institutions belong to the
network of public hospitals of the Basque Health
Care Service, which provides free unrestricted care
to nearly 100% of the population. The hospital staff
was componed of full time hospitalists, physicians
of various specialities qualified on standarized
national residency programs. Every hospital has
intensive care units (ICUs), which are independent
services assisted by specialized physicians. The
emergency room (ER) staff was componed of full
time physicians of diverse specialities, including
primary care physicians. The project was approved
by the hospital ethics review board.
The baseline period for each of the 5 hospitals
included all patients admitted with CAP between
March 1, 1998 and March 1, 1999. We selected
retrospectively all patients admitted with CAP to
one of the hospitals (Hospital E), and a random
sample of the patients admitted with CAP to four
other hospitals (Hospitals A, B, C and D). Sample
size estimates were made to fulfill previous
hypotheses about expected differences in main
process-of-care (appropriate antibiotic, length of
intravenous therapy) and outcome variables (30-
day mortality, length of hospital stay), with a=0.05
and 1b=0.8. A total of 100 patients was selected
in each center. One of the four hospitals utilized
different sampling (140 patients) due to its larger
size (Hospital D). To take into account case
confirmation and exclusion problems and possible
missing data, a 40% oversampling was built in.
For each of the hospitals we also defined a
follow-up period, consisting of all patients ad-
mitted with CAP in the period between March 1,
2000 and September 30, 2001. This was done in
order to assess changes over time in the manage-
ment of patients with CAP. Sample size estimates
and oversampling were devised in a manner similar
to that used for the baseline period. Hospital E was
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the follow-up period it was in the process of
implementing a guideline for the management of
CAP whose goal was to have an impact both on
process-of-care and on outcomes.16 Thus, in the
follow-up period, a total of 150 patients were
selected in each center (A, B and C), except in
Hospital D, where 200 patients were sampled.
In both periods, Hospitals A,B,C, and D had not
implemented guidelines for the management of the
patients admitted with CAP, nor had any explicit
strategies (for example, switching from intravenous
to oral antibiotics and early discharge) been
designed for the care of these patients.Patients
All adult patients (18 years or older) with a CAP
diagnostic admitted to any of the 5 hospitals were
included, as long as CAP was suspected within the
first 24 h after arrival at the ER. Pneumonia was
defined as pulmonary infiltrates on chest radio-
graph not known to be old and symptoms consistent
with pneumonia, including cough, dyspnea, fever,
and/or pleuritic chest pain. Patients with pneumo-
nia were excluded if they were known to be either
positive for the human immunodeficiency virus,
chronically immunosuppressed (defined as immu-
nosuppression for solid organ transplantation,
postsplenectomy, receiving 10mg/day of predni-
sone or the equivalent for430 days, treatment
with other immunosuppressive agents, or neutro-
penic, i.e.,o1.0 109/l neutrophils), or if they had
been hospitalized during the previous 14 days.Retrospective selection
We reviewed retrospectively the clinical history of
all patients admitted with CAP to Hospital E during
the baseline period, as well as the clinical history of
patients randomly selected from the 4 control
hospitals during both periods. Potential pneumonia
cases were identified if they had a principal
discharge diagnosis of pneumonia (International
Classification of Disease, Ninth Revision, Clinical
Modification (ICD-9-CM) codes 480.0–480.9, 481,
482.0–482.9, 483.0–483.8, 485, 486, 487.0, or
507.0; or a principal discharge diagnosis of respira-
tory failure (ICD-9-CM code, 518.81) and a second-
ary diagnosis of pneumonia. Case confirmation
required that the patient have an appropriate
ICD-9-CM code, diagnostic suspicion of CAP during
the first 24 h after arrival at the ER, a clinician-
documented diagnosis of pneumonia, and a chest X-
ray consistent with CAP.Each chart was reviewed and abstracted by two
trained reviewers using a structured questionnaire
form. The two physicians were trained to retrieve
data from the medical record in a similar way and
were tested for agreement with each other. They
were provided with a manual that included the
definitions of all variables and categories. A
member of the research team (P.P.E) reviewed a
sample of 40 records for all variables and
checked those deemed more relevant (vital status,
intensive care unit admission, length of stay,
Pneumonia Severity Index (PSI),17 30-day read-
mission), to evaluate the accuracy of the
data retrieved by the reviewers. In addition,
the two reviewers each reviewed 40 additional
records for the same variables to test for agree-
ment with each other. We found Kappa and intra-
class correlation coefficients higher than 0.99 in
all cases.Baseline patient characteristics and outcome
variables
All patients’ clinical and demographic character-
istics and their previous antibiotic treatment were
recorded. To measure the severity of CAP, we used
independently the PSI17 and CURB-6518 scores
(Confusion; Urea47mmol/l; Respiratory rate4
30/min; Blood pressure, systolico90mm Hg or
diastolico60mmHg; age465). We recorded
information on all the variables of the PSI score
and the variables included in the CURB-65
score. For the PSI score calculation, all lost data
or unperformed lab tests were considered to be
normal. Classes of PSI and CURB-65 were created
according to the original authors’ classifica-
tions.17,18 We defined severe CAP (SCAP) as the
presence of at least two of the following minor
criteria (systolic blood pressureo90mm Hg, multi-
lobar involvement, PaO2/FiO2 o250),or one of two
major criteria (requirement of mechanical ventila-
tion, presence of septic shock), as defined by other
authors.19
Process-of-care variables included (1) initial
antibiotic treatment consistent with the recom-
mendations of the Spanish Society of Pneumology
and Thoracic Surgery,20 which are similar to those
of the American Thoracic Society or the Infectious
Diseases Society of America;21,22 (2) coverage of
atypical pathogens (including treatment with
macrolides or levofloxacin and similars); (3) anti-
biotic administration within 8 h of arrival at the
Emergency Room; (4) total duration of antibiotic
therapy; and (5) duration of intravenous antibiotic
therapy.
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discharge and at 4 weeks; (2) admission to the
intensive care unit; (3) use of a mechanical
ventilator; (4) septic shock (defined as systolic
arterial tension lower than 90mmHg and requiring
vasopressors for a minimum of 4 h); (5) hospital
readmission within 4 weeks due to pneumonia-
related complications; (6) length of stay (calcu-
lated as the discharge date minus the admission
date).Statistical methods
Descriptive statistics included frequency, percen-
tages, mean, median, and standard deviations.
Socio-demographic factors, clinical and laboratory
findings, the disease severity, and the process of
care and outcome results are presented by hospi-
tal. For comparison of categorical variables among
hospitals during the baseline period, the Chi-Square
test was employed. For continuous variables an
ANOVA test and a non-parametrics test (Kruskal–-
Wallis) were employed.
For the adjusted models, in the baseline period,
the main categorical independent variable was the
hospitals. In all models the comparison group was
Hospital E. For continuous dependent variables
(duration of antibiotic therapy, duration of anti-
biotic intravenous therapy, and length of stay),
multivariable linear regression models were em-
ployed. Due to the non-normal distribution of these
dependent variables, a log transformation was
performed. Parameter estimates and standard
errors were estimated after exponentiation. For
all other dependent variables, all dichotomous,
multivariate exact logistic regression models were
employed.23 Odds ratios (OR) and 95% confidence
intervals (95% CI) are presented. Adjustments by
disease severity (measured by the PSI score as a
continuous variable), multilobar radiological invol-
vement, antecedents of chronic obstructive pul-
monary disease (COPD) and antibiotic treatment
previous to hospital admission were performed for
all models.
For the adjusted models in the secular trends
part of the study, analyses were done by hospital.
The main categorical independent variable was the
period of study (follow-up versus baseline period,
with the latter used as the comparison category).
Otherwise, regression models (linear or logistic
depending on the dependent variable) and adjust-
ments were made in much the same way as in the
previous analysis.
The same adjusted multivariate analyses as
described previously were performed again, thistime using for adjustment the CURB-65 categories
as a measure of severity instead of the PSI score.Results
Table 1 presents the selection process used to
identify patients for both the baseline period and
the follow-up period, according to hospital. Alto-
gether, a total of 1498 patients were included, 844
for the baseline period and 654 for the follow-up
period. For Hospital A, for both periods, the case
confirmation rate was lower than for all other
hospitals, since there were minor codification
errors.
Patient characteristics and disease severity
in baseline period
Table 2 shows the clinical and demographic
characteristics of patients admitted to each of
the hospitals during the baseline period. We found
statistically significant differences among the 5
hospitals in some of the patient factors, including
average age; history of cerebrovascular disease and
COPD; and presence of PaO2o60mmHg. Patients
admitted to Hospital C were younger on average,
and were less likely to have a history of COPD or
PaO2o60mmHg.
The disease severity for patients admitted to
each hospital during the baseline period is shown
on Table 3. Statistically significant differences
between hospitals were observed in disease sever-
ity when we used the PSI score classification (low-
risk classes I–III; high-risk classes, IV–V). The
differences observed in the PSI score averages
were not statistically significant, nor were statisti-
cally significant differences in severity found using
the CURB-65 groups. There were no significant
differences among hospitals in the frequency of
SCAP.
Process-of-care and outcome performance
between hospitals for the baseline period
Statistically significant differences were observed
among hospitals in the use of antibiotic treatment
(Table 4). Most patients were treated with second-
or third-generation cefhalosporines alone or com-
bined with a macrolid, or only with amoxicilin-
clavulanic.
Table 5 shows the performance of process of care
and outcomes among hospitals. Statistically sig-
nificant differences were observed among hospitals
in all process-of-care variables measured except in
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Table 1 Sample parameter selection in both periods*.
Hospital A Hospital B Hospital C Hospital D Hospital E
N (%) N (%) N (%) N (%) N (%)
Baseline period
Potential pneumonia casesy 479 524 527 836 502
Selected random sample 164 (34.4) 133 (25.4) 124 (23.5) 193 (23.1) —
Case confirmation of pneumoniaz 134 (81.7) 125 (94) 124 (1 0 0) 175 (90.7) 453 (90.2)
Cases excludedy 35 (21.3) 16 (12) 14 (11.3) 26 (13.5) 76 (15.1)
Patients included 99 (60.4) 109 (82) 110 (88.7) 149 (77.2) 377 (75.1)
Follow-up period
Potential pneumonia casesy 795 813 872 1331
Selected random sample 231 (29.1) 185 (22.8) 177 (20.3) 268 (20.1)
Case confirmation of pneumoniaz 190 (82.3) 170 (91.9) 169 (95.5) 244 (91)
Cases excludedy 38 (16.5) 26 (14.1) 19 (10.7) 36 (13.4)
Patients included 152 (65.8) 144 (77.8) 150 (84.7) 208 (77.6)
*Data are given in numbers (and percentages). For Hospital E, the entire baseline period sample was included, although this
hospital was excluded from the follow-up period due to the implementation of guidelines for CAP during this period.
yPotential pneumonia cases were identified if they had a principal discharge diagnosis of pneumonia (International
Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes 480.0–480.9, 481, 482.0–482.9, 483.0–483.8,
485, 486, 487.0, and 507.0); or a principal discharge diagnosis of respiratory failure (ICD-9-CM code 518.81) and a secondary
diagnosis of pneumonia.
zCase confirmation required that the patient have an appropriate ICD-9-CM code, diagnostic suspicion of CAP during the first
24 h after arrival at the Emergency Room, a clinician-documented diagnosis of pneumonia, and a chest X-ray consistent with
CAP.
yExclusion criteria are provided in the Methods section.
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antibiotic treatment differed by more than 3 days
across hospitals (mean duration,16.6 versus 12.9
days), and the duration of intravenous treatment
differed by more than 4 days (mean duration,7.9
versus 3 days).
No statistically significant differences were ob-
served among hospitals in outcomes of interest
such as 30-day mortality, in-hospital mortality, and
septic shock. Variability was found however in the
use of intensive care units and the need for a
mechanical ventilation. The mean age of the
patients admitted to the ICU was 58.8 years; of
these, 17.9% were older than 70 years. Among the
total number of patients with CAP older than 64
years, 1.8% were admitted to the ICU. One of the
hospitals (Hospital A) had a significantly higher
percentage of patients readmitted within 30 days.
Statistically significant differences between hospi-
tals were also found in the length of stay
(Po0.001), with differences that exceeded 3 days
in the unadjusted mean length of stay (ranging
from 10.6 to 7.3 days).
An analysis adjusted by PSI score, multilobar
radiological involvement, history of COPD, and
antibiotic treatment prior to hospital admission
confirmed that no significant differences betweenhospitals were found in 30-day mortality, in-
hospital mortality, or septic shock. The adjusted
30-day readmission rate for Hospital A was higher
than that found in Hospital E, which had the lowest
length of stay (OR, 4.31; 95% CI, 1.4–12.8). In
addition, the adjusted analyses confirmed signifi-
cant differences among the hospitals in mean
length of stay of up to 2.9 days (9.2 versus 6.3
days; adjusted Po0.0001), mean length of intra-
venous therapy (7.5 versus 2.6; Po0.0001) , and
total length of antibiotic therapy (15.7 versus 12.3
days; Po0.0001).
Adjusting for CURB-65 scores in all the pre-
vious analyses instead of the PSI score yielded
statistical results similar to those obtained with the
PSI score.Secular changes between both periods
During the follow-up period there was a significant
increase in the use of new quinolones (levofloxacin
and similar agents) in each of the 4 hospitals
included in this analysis. In the 4 hospitals
altogether the use of the new quinolones rose from
0.4% to 8.4% (Po0.0001). Significant differences
were also found in the use of other groups of
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Table 2 Demographic and clinical characteristics of patients admitted during the baseline period*.
Characteristics Hospital A Hospital B Hospital C Hospital D Hospital E P-value
(n=99) (n=109) (n=110) (n=149) (n=377)
Demographic findings
Age, mean (std), in years 70.1 (18.5) 68.9 (16.7) 64.4 (18.7) 71.2 (17.7) 67.1 (18.2) 0.02
Ageo50 years 16 (16.2) 14 (12.8) 24 (21.8) 21 (14.1) 65 (17.2) 0.40
Female sex 37 (37.4) 38 (34.9) 50 (45.5) 60 (40.3) 142 (37.7) 0.53
Nursing home resident 8 (8.1) 6 (5.5) 7 (6.4) 12 (8.1) 22 (5.8) 0.84
Previous antibiotic therapy 29 (29.3) 32 (29.4) 32 (29.1) 29 (19.5) 90 (23.9) 0.22
Underlying diseases
Neoplastic disease 6 (6.1) 10 (9.2) 8 (7.3) 11 (7.4) 12 (3.2) 0.08
Liver disease 3 (3) 7 (6.4) 3 (2.7) 7 (4.7) 9 (2.4) 0.28
Congestive heart failure 9 (9.1) 11 (10.1) 15 (13.6) 22 (14.8) 30 (8) 0.14
Cerebrovascular disease 20 (20.2) 12 (11) 11 (10) 16 (10.7) 68 (18) 0.03
Renal disease 3 (3) 2 (1.8) 3 (2.7) 7 (4.7) 13 (3.5) 0.77
Chronic obstructive pulmonary disease 29 (29.3) 28 (25.7) 17 (15.5) 45 (30.2) 121 (32.5) 0.01
Diabetes mellitus 7 (7.1) 14 (12.8) 17 (15.5) 25 (16.8) 54 (14.5) 0.26
Number of comorbid conditions
1 41 (41.4) 40 (36.7) 38 (34.6) 54 (36.2) 151 (40.1) 0.75
2 or more 16 (16.2) 19 (17.4) 16 (14.6) 35 (23.5) 72 (19.1) 0.40
Physical examination findings
Altered mental status 8 (8.1) 14 (12.8) 14 (12.7) 13 (8.7) 34 (9) 0.56
Pulse X125/min 12 (12.5) 7 (6.5) 4 (4) 12 (8.6) 26 (7.2) 0.24
Respiratory rate X30/min 13 (35.1) 17 (23) 20 (28.2) 45 (43.3) 76 (35) 0.06
Systolic blood pressure o90mmHg 3 (3.1) 3 (2.8) 3 (2.8) 4 (2.8) 4 (1.2) 0.68
Temperature o35 1C or X40 1C 1 (1) 1 (0.9) 1 (0.9) 1 (0.7) 3 (0.9) 1
Laboratory and radiological findings
Blood urea nitrogen430mg/dl 33 (34.7) 27 (25) 25 (26) 46 (31.9) 103 (27.5) 0.44
Glucose X250mg/dL 7 (7.5) 6 (5.6) 13 (13.3) 12 (8.2) 33 (9.1) 0.38
Haematocrit o30% 2 (2.1) 5 (4.6) 0 (0.0) 3 (2.1) 6 (1.7) 0.21
Sodiumo130mmol/l 6 (6.5) 2 (1.9) 5 (5.3) 5 (3.5) 19 (5.8) 0.42
PaO2o60mmHg 59 (68.6) 33 (33.3) 25 (26.6) 62 (46.6) 155 (42.6) o0.001
Arterial ph o7.35 3 (3.5) 7 (7.07) 12 (12.50) 7 (5.26) 22 (6.32) 0.13
Pleural effusion 5 (5.1) 5 (4.6) 7 (6.4) 13 (8.7) 43 (11.4) 0.08
Multilobar pneumonia 27 (27.3) 23 (21.3) 27 (24.6) 43 (28.9) 71 (18.8) 0.09
*Data are given as numbers (percentage) unless otherwise indicated. Percentages exclude patients with missing data.
CAP management variability 273antibiotics in Hospital C (amoxicillin–clavulanic,
27.1% to 45.6%, Po0.01; cephalosporine 2nd or 3rd
generation, 37.4% to 16.8%, Po0.001).
No more significant differences were found in the
process-of-care performance between baseline and
follow-up periods (Table 6). The changes in out-
comes indicators showed that in Hospital B 30-day
mortality and in-hospital mortality increased
8.89% (P=0.04), and septic shock increased 4.86%
(P=0.02). In adjusted analyses, however, the only
significant differences between the two periods
found for any of the hospitals was a reduction in the
rate of 30-day readmission for Hospital A (OR, 0.25;
95% CI, 0.06–0.96) and a reduction in the duration
of antibiotic therapy for Hospital B (adjusted
analysis; 0.38 days, P=0.04), dissapearing thedifferences in 30-day mortality, in-hospital mortal-
ity and septic shock found previously in the
univariate analysis.
Adjusting by CURB-65 scores in the previous
analyses yielded results similar to those obtained
by adjusting with the PSI score.Discussion
This study reveals significant differences between 5
hospitals in a single geographic area in the manage-
ment of patients admitted with CAP and identifies
important areas for improvement. Differences
observed in relevant process and outcome of care
ARTICLE IN PRESS
Table 4 Use of antibiotics by hospitals during the baseline period*.
Antibiotics Hospital A Hospital B Hospital C Hospital D Hospital E P-value
(n=99) (n=109) (n=110) (n=149) (n=377)
Macrolids 4 (4.1) 9 (8.3) 7 (6.5) 10 (6.9) 71 (18.9) o0.001
Amoxicillin-Clavulanic 34 (34.7) 30 (27.8) 29 (27.1) 36 (25) 158 (42.1) o0.001
Cephalosporine 2nd or
3rd generation
30 (30.6) 42 (38.9) 40 (37.4) 40 (27.8) 54 (14.4) o0.001
Cephalosporine 2nd or
3rd generation+macrolids
20 (20.4) 16 (14.8) 27 (25.2) 38 (26.4) 47 (12.5) o0.01
Others 10 (10.2) 11 (10.2) 4 (3.7) 20 (13.9) 45 (12) 0.11
*Data are given as numbers (and percentages). Percentages exclude patients with missing data.
Table 3 Severity of illness of patients admitted in baseline period*.
Hospital A Hospital B Hospital C Hospital D Hospital E P-value
(n=99) (n=109) (n=110) (n=149) (n=377)
PSI, mean (std)y 92.2 (35.1) 89.6 (37.7) 83.6 (37.7) 95.2 (36) 87.3 (36.1) 0.08
PSI Classy
I–III 45.5 56 65.5 45.6 57.3 o0.01
IV–V 54.6 44 34.6 54.4 42.7 o0.01
CURB-65y
Group 1 58.6 65.1 69.1 56.4 66.3 0.13
Group 2 32.3 23.9 21.8 27.5 24.4 0.42
Group 3 9.1 11 9.1 16.1 9.3 0.20
SCAPz 13.1 5.5 11.8 12.1 9.3 0.31
*Data are given as percentages unless otherwise indicated.
ySeverity of illness was assessed using the Pneumonia Severity Index (PSI) and CURB-65 score. Patients in PSI classes I–III have
the lowest severity and mortality, while classes IV–V have the highest severity and risk. CURB-65 Group 1 patients have the
lowest mortality, and Group 3 the highest mortality.
zSevere community-acquired pneumonia (SCAP) was defined as the presence of two or three minor criteria (systolic blood
pressure o90mm Hg, multilobar involvement, PaO2/FiO2 o250) or one of two major criteria (requirement of mechanical
ventilation, presence of septic shock).
A. Capelastegui et al.274variables cannot be explained by patient-related
factors alone. In addition, after analyzing the
evolution of these variables across two time
periods, secular trends were minimal and hospi-
tal-specific differences remain.
To our knowledge, this is the first assessment of
variability and secular trends in CAP management
conducted in Europe. The strength of this study is
the use of process-of-care variables based on
current evidence together along with outcome
results. In addition, we included unselected adults
of all ages, and all hospitals in the study belonged
to the same public health system and had similar
types of human and technological resources avail-
able.
Our results are similar to those found in studies
carried out in North America.1–4 We found asignificant difference in adjusted length of stay
between the 5 hospitals in this study. The median
length of stay ranged from 6 to 10 days across
hospitals, and mean adjusted length of stay varied
between 2.9 days and 1.4 days longer than that
found at the shortest length of stay hospital.
Importantly, these interhospital differences in
length of stay were not associated with differences
in major clinical outcomes. Prior studies suggest
that less than 25% of this variation can be
attributed to disease severity or other identifiable
patient or hospital factors.2 Even though our study
does not show the causes behind the variability
found among hospitals, it suggests, as have
previous studies,1–3 that reductions in length of
stay of patients treated for CAP at the hospitals
with a longer length of stay would not significantly
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Table 5 Comparison between hospitals for performance of process of care and outcomes in baseline period*.
Hospital A Hospital B Hospital C Hospital D Hospital E P value
(n=99) (n=109) (n=110) (n=149) (n=377)
Process of care
Appropriate antibioticy 87 (88.8) 90 (83.3) 96 (89.7) 121 (84) 269 (71.4) o0.001
Coverage of atypical
pathogensz
31 (31.3) 31 (28.4) 35 (31.8) 64 (43.8) 137 (36.5) 0.08
Antibiotic within 8 h 65 (77.4) 62 (59.6) 77 (73.3) 105 (84) 202 (59.9) o0.001
Length of antibiotic therapy,
mean (std), in daysy
14.7 (6.3) 14.2 (4.6) 16.4 (5.9) 13.9 (5.3) 12.9 (6.3) o0.001
Length of intravenous therapy,
mean (std), in daysy
4.7 (2.6) 3 (2.9) 6.5 (5.1) 7.9 (5.4) 4.5 (5.5) o0.001
Outcomes
30-day mortality 11 (11.1) 10 (9.2) 11 (10) 12 (8.1) 39 (10.3) 0.93
In-hospital mortality 7 (7.1) 10 (9.2) 10 (9.1) 12 (8.1) 36 (9.6) 0.94
Intensive care unit admission 3 (3.0) 3 (2.8) 8 (7.3) 0 (0) 14 (3.7) 0.03
Mechanical ventilation 2 (2.0) 0 (0.0) 5 (4.6) 0 (0.0) 10 (2.7) 0.05
Septic shockJ 0 (0) 0 (0) 2 (1.8) 2 (1.3) 6 (2.0) 0.49
30-day readmission 7 (7.1) 2 (1.8) 4 (3.6) 2 (1.3) 7 (1.9) 0.04
Length of hospital stay (days)y
Mean (SD) 8.8 (5.1) 7.9 (6.4) 8.4 (6.4) 10.6 (5.3) 7.3 (5.8) o0.001
Median 8 6 7 10 6 o0.001
*Data are given as numbers (and percentages) unless otherwise indicated. Percentages exclude patients with missing data.
yAppropriate antibiotic is defined as usage of an antibiotic recommended in the guidelines of the American Thoracic Society or
the Infectious Diseases Society of America.
zCoverage of atypical pathogens is defined as cases when antibiotic treatment included a macrolid, or a new quinolone.
JSeptic shock is defined as arterial systolic tension lower than 90mmhg and the need for vasopressors for a minimum of 4 h.
yCases resulting in death are excluded.
CAP management variability 275affect clinical outcomes. In turn, a 1-day reduction
in length of stay might yield substantial cost-
savings.24
The variability found in our study may also be
common at other European hospitals. In a recent
study of Swedish hospitals, which compared 17
departments of infectious diseases, significant
differences were found for CAP among hospitals in
unadjusted mortality and unadjusted length of stay
(median ranged from 4.5 to 7 days).25 When
individual sites were compared, no correlations
were found between mean PSI score and mean
length of stay or between mean PSI score and
mortality rate. This suggests the possibility that
differences may exist in quality of care between
institutions. Another recent study that compared 4
hospitals in Spain found significant differences in
the length of stay that were independent of the
severity of the patients illness.26
Upon measuring the process-of-care factors, we
found that most patients were treated with
antibiotics according to established guidelines.20–22
This agrees with findings reported in other stu-
dies.2,27,28 However, we found significant differ-ences in the duration of both antibiotic and
intravenous antibiotic treatment. For all hospitals,
the small percentage of patients who received an
antibiotic within the first 8 h was striking, given
that this is a well-known process-of-care factor
correlated with positive relevant outcomes.29,30
The ICU admission rate also varied significantly
among hospitals, and in some of them was strikingly
lower than observed in other studies.19 In our study,
one of the hospitals had a 7.3% ICU admission rate
while the rate was less than 4% in the rest of the
hospitals. The severity of illness among patients
admitted to our hospitals was lower than that found
in other studies,18,31 which could justify, partly, the
low rate of ICU admission. However, although we do
not have a good indicator in order to assess the
decision about ICU admission, we have some data
suggesting underuse of the ICU. The percentage of
patients older than 64 years old admitted to the ICU
(1.8%) and the mean age of the total number of
patients admitted to the ICU (58.8 years) are lower
than those reported in other studies.19,32 In our
case, older age is likely to have been used as a
restrictive criterion for ICU admission. Nevertheless,
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Table 6 Secular changes between both periods in each hospital. Process of care and outcomes indicators*.
Hospital A P-value Hospital B P-value Hospital C P-value Hospital D P-value
Process of care
Appropriate antibioticy 0.27 0.95 6.18 0.15 0.21 0.96 6.26 0.08
Coverage of atypical pathogensz 2.90 0.63 4.2 0.47 2.85 0.63 2.79 0.60
Antibiotic within 8 h 1.08 0.85 10.1 0.10 0.23 0.97 0.24 0.95
Length of antibiotic therapyy 0.17 0.83 1.09 0.08 0.16 0.83 0.28 0.67
Length of intravenous therapyy 0.17 0.72 0.15 0.68 0.27 0.67 0.8 0.23
Outcomes
30-day mortality 0.07 0.99 8.89 0.05 0.67 0.86 1.32 0.64
In-hospital mortality 3.46 0.35 8.89 0.05 0.24 0.95 1.32 0.64
Intensive care unit admission 0.40 0.85 0.72 0.75 0.60 0.85 2.40 0.06
Mechanical ventilation 0.05 0.98 2.78 0.08 1.88 0.41 1.92 0.09
Septic shockJ 1.97 0.16 4.86 0.02 2.18 0.31 1.54 0.33
30-day readmission 4.44 0.09 0.95 0.63 2.97 0.09 0.10 0.94
Length of hospital stayy
Mean, differences in days 0.25 0.71 1.27 0.09 0.72 0.35 0.62 0.39
Median, differences in days 0 0.91 0 0.23 1 0.20 1 0.79
*Data are given as the difference in percentage between baseline and follow-up periods. Length of antibiotic therapy, length
of intravenous therapy and length of hospital stay are given as the difference in days between baseline and follow-up periods.
yAppropriate antibiotic is defined as usage of an antibiotic recommended in the guidelines of the American Thoracic Sosiety or
the Infectious Diseases Society of America.
zCoverage of atypical pathogens is defined as cases when antibiotic treatment included a macrolid, or a new quinolone.
ySeptic shock is defined as arterial systolic tension lower than 90mmHg and the need for vasopressors for a minimum of 4 h.
JCases resulting in death are excluded.
A. Capelastegui et al.276there is information supporting the belief that care
given to critically ill elderly patients in ICU is
justified.33 Therefore, we consider it would be
necessary to carry out a prospective study of
criteria used to admit the patients diagnosed with
CAP in our ICUs.
Comparing the same process of care and outcome
variables for CAP patients between two periods of
time revealed few statistically significant differ-
ences. These results contrast with studies done in
the USA, where secular trends showing improve-
ment in process of care and outcomes were found,
probably because of a more competitive environ-
ment than that in our study.14,15 It is quite possible
that the null secular trends we observed would be
replicated in other European hospitals, which
would suggest the need for hospital staff to better
acquaint themselves with current processes of care
in order to identify areas for improvement and to
improve compliance with clinical practice guide-
lines.10–12,34
Our study has several limitations. First, medical
record documentation and chart review could have
introduced flaws. However, the reliability between
the abstractors was measured and found to be
excellent. The outcome indicators used are highly
objective endpoints that were available for all ofthe patients. Similarly, the identification of CAP
cases was probably free from bias since case
confirmation required clinician-documented diag-
nosis and chest X-ray consistent with CAP. Secondly,
although we included important outcomes, we did
not measure others that are also relevant, such as
resolution of symptoms, return to work, or return
to daily activities. Third, although we used a
validated, pneumonia-specific index to adjust for
disease severity, we may not have adjusted fully for
differences among patients. Fourth, since we did
not take into account CAP patients released from
the Emergency Room and managed as outpatients,
we were not able to evaluate the admission
decision. However, the differences found among
hospitals in the severity of admitted patients using
PSI scores17 do suggest differences in the criteria
used for the admission decision.Conclusions
We found significant differences in the manage-
ment of CAP between 5 hospitals that cannot be
attributed to differences in disease severity, co-
morbidity factors, or patients’ sociodemographic
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CAP management variability 277characteristics. Patients treated at hospitals with a
shorter length of stay had similar clinical outcomes,
which suggest possible improvements for hospitals
with historically higher average lengths of stay. The
observation of limited, if any, secular trends
between the two time periods indicates that
knowledge of current processes of care and
compliance with guideline recommendations are
basic requirements for improving the quality of
medical treatment for patients with CAP.Acknowledgments
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